Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25581025
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and
comparison to de novo Hodgkin lymphoma
#MMPMID25581025
Parikh SA
; Habermann TM
; Chaffee KG
; Call TG
; Ding W
; Leis JF
; Macon WR
; Schwager SM
; Ristow KM
; Porrata LF
; Kay NE
; Slager SL
; Shanafelt TD
Am J Hematol
2015[Apr]; 90
(4
): 334-8
PMID25581025
show ga
Although transformation to Hodgkin lymphoma (HL) is a recognized complication in
patients with chronic lymphocytic leukemia (CLL), its incidence, clinical
characteristics and outcomes are not well defined. We used the Mayo Clinic CLL
and Lymphoma Databases to identify CLL patients who developed biopsy-proven HL
(CLL/HL) on follow-up, as well as cases of de novo HL (i.e., without prior CLL).
Among 3887 CLL patients seen at Mayo Clinic from January 1995 through August
2011, 26 (0.7%) developed HL. In a nested cohort of 2,465 newly diagnosed CLL
patients followed prospectively, the incidence of HL was 0.05%/year (10 year risk
= 0.5%). The median overall survival (OS) from date of HL diagnosis in patients
with CLL/HL was 3.9 years compared to not reached for de novo HL patients (n =
709) seen during the same time interval (P < 0.001). The shorter OS of CLL/HL
patients persisted after adjusting for differences in age and Ann Arbor stage of
disease. The International Prognostic score (IPS) developed for de novo HL
stratified prognosis among CLL/HL patients with median survival of not reached,
6.2, 2.4, and 0.3 years (P = 0.006) for those with IPS scores of ?2, 3, 4, and
?5, respectively. In summary, approximately 1 of every 200 CLL patients will
develop HL within 10 years. Survival after HL diagnosis in patients with CLL is
shorter than de novo HL patients. The IPS for de novo HL may be useful for
stratifying survival in CLL/HL patients.
|Aged
[MESH]
|Aged, 80 and over
[MESH]
|Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse
effects/*therapeutic use
[MESH]
free
free
free
